MARTINSRIED/MUNICH (Germany), Feb. 28 /PRNewswire-FirstCall/ -- WALTHAM,
Mass. and PRINCETON, N.J., -- GPC Biotech AG (Frankfurt Stock Exchange: GPC;
TecDAX index; Nasdaq: GPCB) today announced that the Company will give a
corporate presentation at the upcoming Cowen & Co. 26th Annual Health Care
Conference in Boston, MA as well as at the Ninth Annual Lehman Brothers Global
Healthcare Conference in Miami, FL.
The presentation at the Cowen & Co. 26th Annual Health Care Conference
will take place on Tuesday, March 7, 2006 at 8 AM EST at The Boston Marriott
Copley Place in Boston, MA.
The presentation at the Ninth Annual Lehman Brothers Global Healthcare
Conference is scheduled for Wednesday, March 8, 2006 at 9 AM EST at the Loews
Miami Beach Hotel in Miami, Florida.
The company presentations at both conferences will be webcast live and
will be accessible through the GPC Biotech Web site at
http://www.gpc-biotech.com. A replay will also be available via the Web site.
GPC Biotech AG is a biopharmaceutical company discovering and developing
new anticancer drugs. The Company's lead product candidate -- satraplatin --
has achieved target enrollment in a Phase 3 registrational trial as a second-
line chemotherapy treatment in hormone-refractory prostate cancer. The U.S.
FDA has granted fast track designation to satraplatin for this indication, and
GPC Biotech has begun the rolling NDA submission process for this compound.
GPC Biotech is also developing a monoclonal antibody with a novel mechanism-
of-action against a variety of lymphoid tumors, currently in Phase 1 clinical
development, and has ongoing drug development and discovery programs that
leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered
in Martinsried/Munich (Germany). The Company's wholly owned U.S. subsidiary
has sites in Waltham, Massachusetts and Princeton, New Jersey. For additional
information, please visit the Company's Web site at
http://www.gpc-biotech.com.
For further information, please contact:
GPC Biotech AG
Martin Braendle
Associate Director, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565-2693
ir@gpc-biotech.com
In the U.S.: Laurie Doyle
Associate Director, Investor Relations & Corporate Communications
Phone: +1 781-890-9007 X267
usinvestors@gpc-biotech.com
SOURCE GPC Biotech AG
 back to top
Related links:
http://www.gpc-biotech.com
CONTACT:
Martin Braendle, Associate Director, Investor
Relations & Corporate Communications, +49 (0)89 8565-2693,
ir@gpc-biotech.com, or Laurie Doyle, Associate Director, Investor
Relations & Corporate Communications, +1- 781-890-9007, ext. 267,
usinvestors@gpc-biotech.com, both of GPC Biotech AG
|
